Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
37832
CAS Number:
1110813-31-4
Dacomitinib
Purity:
≥ 98 % (HPLC)
Synonym(s):
Número de pieza 00299804, ( E )- N -[4-[(3-Cloro-4-fluorofenil)amino]-7-metoxiquinazolin-6-il]-4-(piperidin-1-il)but-2-enamida
Documents
$201.60 /50 mg
Tamaño
Request Bulk Quote
Información del producto

Dacomitinib is a potent and selective irreversible inhibitor of the epidermal growth factor receptor (EGFR), primarily utilized in the treatment of non-small cell lung cancer (NSCLC). This compound is particularly effective against tumors with specific EGFR mutations, making it a valuable option for targeted therapy. Dacomitinib's unique mechanism of action allows for sustained inhibition of EGFR signaling pathways, which can lead to improved clinical outcomes in patients who have not responded to traditional therapies.

In addition to its application in oncology, Dacomitinib is being explored in combination therapies to enhance its efficacy and overcome resistance mechanisms in cancer treatment. Its favorable pharmacokinetic profile and ability to penetrate the blood-brain barrier also position it as a promising candidate for addressing central nervous system metastases. Researchers and healthcare professionals can leverage Dacomitinib's targeted action to optimize treatment regimens and improve patient quality of life.

Número CAS
1110813-31-4
Fórmula molecular
C24H25ClFN5O2
Peso molecular
469.95
Número MDL
MFCD19443734
Condiciones
Conservar a < 0 °C
Información general
Número CAS
1110813-31-4
Fórmula molecular
C24H25ClFN5O2
Peso molecular
469.95
Número MDL
MFCD19443734
Condiciones
Conservar a < 0 °C
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Dacomitinib is widely utilized in research focused on:

  • Targeted Cancer Therapy: This compound is primarily used in the treatment of non-small cell lung cancer (NSCLC). By inhibiting specific pathways, it helps to block tumor growth and spread, offering a more effective treatment option compared to traditional chemotherapy.
  • Clinical Trials: Dacomitinib is frequently involved in clinical trials aimed at evaluating its efficacy and safety in various cancer types. Researchers benefit from its targeted action, which allows for more precise patient selection and potentially better outcomes.
  • Personalized Medicine: The use of Dacomitinib supports the growing field of personalized medicine, where treatments are tailored based on genetic markers. This approach enhances treatment effectiveness and minimizes side effects for patients with specific mutations.
  • Combination Therapies: It is often studied in combination with other therapeutic agents to improve treatment regimens. This strategy can lead to synergistic effects, increasing the overall effectiveness against resistant cancer types.
  • Research on Resistance Mechanisms: Dacomitinib is valuable in research aimed at understanding resistance mechanisms in cancer therapies. Insights gained can guide the development of next-generation inhibitors and improve treatment strategies.

Citas